IDOV-Immune for Advanced Solid Tumors
NCT06910657
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colorectal Cancer
- Pancreatic Cancer
- Melanoma
- Ovarian Cancer
- Gastric Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Breast Cancer
- Sarcoma
- Bladder Cancer
- Lung Cancer
- Prostate Cancer
- Cervical Cancers
- Head and Neck Cancers
- Adrenal Gland Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- ViroMissile, Inc.
- Last updated on ClinicalTrials.gov
- August 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- South Texas Accelerated Research Therapeutics · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.